JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on March 8, 2006; DOI: 10.1124/jpet.105.095133


0022-3565/06/3173-980-988$20.00
JPET 317:980-988, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.095133v1
317/3/980    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Das, S.
Right arrow Articles by Das, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Das, S.
Right arrow Articles by Das, D. K.

CARDIOVASCULAR

Potentiation of a Survival Signal in the Ischemic Heart by Resveratrol through p38 Mitogen-Activated Protein Kinase/Mitogen- and Stress-Activated Protein Kinase 1/cAMP Response Element-Binding Protein Signaling

Samarjit Das, Arpad Tosaki, Debasis Bagchi, Nilanjana Maulik, and Dipak K. Das

Cardiovascular Research Center, University of Connecticut School of Medicine, Farmington, Connecticut (S.D., N.M., D.K.D.); Department of Pharmacology, University of Debrecen, Debrecen, Hungary (S.D., A.T.); and Department of Pharmacy, Creighton University, Omaha, Nebraska (D.B.)

Resveratrol (3,4',5-trihydroxy-trans-stilbene), a naturally occurring polyphenolic compound found abundantly in grape skins and red wines, has been found to pharmacologically precondition the heart against ischemia reperfusion injury through the potentiation of a survival signal involving cAMP response element-binding protein-dependent phosphatidylinositol 3-kinase-Akt-BclII pathway. The present study was designed to determine whether, similar to ischemic preconditioning, resveratrol uses mitogen-activated protein kinases (MAPKs) as upstream signaling targets. The isolated rat hearts were preperfused for 15 min with Krebs-Henseleit bicarbonate buffer in the absence (control) or presence of extracellular signal-regulated kinase (ERK) 1/2 inhibitor 2'-amino-3'-methoxyflavone (PD98059), p38 MAPK inhibitor 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole (SB-202190), mitogen- and stress-activated protein kinase 1 (MSK-1) inhibitor N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline (H89), protein kinase A inhibitor (9S,10S,12R)-2,3,9,10,11,12-hexahydro-10hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3fg: 3',2',1'-kl]-pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid hexyl ester (KT5720), resveratrol only, resveratrol plus PD98059, resveratrol plus SB-202190, resveratrol plus H89, or resveratrol plus KT5720. Consistent with previous reports, resveratrol provided cardioprotection as evidenced by its ability to improve postischemic ventricular function, reduction of myocardial infarct size, and cardiomyocyte apoptosis. The cardioprotection afforded by resveratrol was partially abolished with PD98059 or SB-202190, suggesting that ERK1/2 and p38 MAPK play roles in resveratrol-mediated preconditioning. An MSK-1 inhibitor, H89, abolished resveratrol-mediated preconditioning, indicating MSK-1 to be the downstream target molecule for both ERK1/2 and p38 MAPK. KT5720 had no effect on resveratrol-mediated cardioprotection. Corroborating these results, Western blot analysis revealed phosphorylation of ERK1/2, p38 MAPK, MAPK-activated protein (MAPKAP) kinase 2, and MSK-1 with resveratrol and inhibition of phosphorylation with corresponding inhibitors. These results showed for the first time that resveratrol triggers an MAPK signaling pathway involving ERK1/2 and p38 MAPK, the former using MSK-1 as the downstream target and the latter, using both MAPKAP kinase 2 and MSK-1 as downstream targets.


Received September 2, 2005; accepted March 7, 2006.

Address correspondence to: Dipak K. Das, Cardiovascular Research Center, University of Connecticut, School of Medicine, Farmington, CT 06030. E-mail: ddas{at}neuron.uchc.edu




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Das, F. N. Salloum, L. Xi, Y. J. Rao, and R. C. Kukreja
ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice
Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1236 - H1243.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. Lekli, G. Szabo, B. Juhasz, S. Das, M. Das, E. Varga, L. Szendrei, R. Gesztelyi, J. Varadi, I. Bak, et al.
Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H859 - H866.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Das, I. Lekli, M. Das, G. Szabo, J. Varadi, B. Juhasz, I. Bak, K. Nesaretam, A. Tosaki, S. R. Powell, et al.
Cardioprotection with palm oil tocotrienols: comparision of different isomers
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H970 - H978.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
T. Nagaoka, T. W. Hein, A. Yoshida, and L. Kuo
Resveratrol, a Component of Red Wine, Elicits Dilation of Isolated Porcine Retinal Arterioles: Role of Nitric Oxide and Potassium Channels
Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4232 - 4239.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Moritz, R. Gust, and H. H. Pertz
Characterization of the Relaxant Response to N,N'-Dipropyl-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine in Porcine Coronary Arteries
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 699 - 706.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.